Skip to main content
. Author manuscript; available in PMC: 2020 Apr 15.
Published in final edited form as: Cancer Res. 2019 Jan 8;79(8):1758–1768. doi: 10.1158/0008-5472.CAN-18-1234

Fig. 6. TET1 targeting sensitizes lung cancer cells to therapy-induced senescence and growth reduction.

Fig. 6.

Control vs. TET1 knockdown H1299 cells were incubated with cisplatin (CDDP) or doxorubicin (DOX) 24 h after transfection for 48 h and analyzed for p21 mRNA (A, B). Cells incubated with CDDP or DOX for 96 h (120 h after transfection with control vs. TET1 siRNAs) were analyzed for senescence using the β-galactosidase assay (C) and for total number of cells (D, E). Results are presented as an average of three experiments ±SEM, p *<0.05, **<0.01, or ***<0.001. Statistical comparison was performed for CDDP- vs. TET1 KD+CDDP-treated cells and DOX- vs. TET1 KD+DOX-treated cells. The mechanism of TET1 gene overexpression and function in lung cancer is depicted (F).